Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04083222 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT04083222 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT04083222, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
Interventions
- DRUG Placebo
- DRUG ISIS 757456
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04083222
The ClinicalTrials.gov registry entry for NCT04083222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04083222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04083222 about?
NCT04083222 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx". This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
What is the current status of trial NCT04083222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-11-13. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT04083222?
The interventions under investigation include: Placebo (DRUG), ISIS 757456 (DRUG).
Who is sponsoring clinical trial NCT04083222?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.